Clinical Trials

GenitourinaryHead & NeckLymphoid

300 enrolled

Nasopharyngeal Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

33 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT03930498 2026-05-11

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

68 enrolled

Nasopharyngeal Carcinoma

NCT04436965 2026-05-11

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

266 enrolled

Nasopharyngeal Carcinoma

NCT05340491 2026-05-11

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

212 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT05780372 2026-05-11

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

474 enrolled

Nasopharyngeal Carcinoma

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT06197776 2026-05-11

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Recruiting

50 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT06323239 2026-05-11

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04425265 2026-05-08

Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma

Phase NA Recruiting

500 enrolled

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT02973386 2026-05-07

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Phase 3 Completed

294 enrolled

Nasopharyngeal Carcinoma

NCT03240835 2026-05-07

The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients

Completed

60 enrolled

Nasopharyngeal Carcinoma, Malnutrition

NCT03907826 2026-05-07

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

212 enrolled

Nasopharyngeal Carcinoma

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT05524168 2026-05-07

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

41 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07567742 2026-05-05

Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma

130 enrolled

Nasopharyngeal Carcinoma, Stomatitis, Ulcer

NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

98 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT07565389 2026-05-04

AK112

42 enrolled

Nasopharyngeal Carcinoma

NCT06682442 2026-05-01

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Phase NA Recruiting

66 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT04944914 2026-04-30

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

188 enrolled

Phase NA Active not recruiting

Nasopharyngeal Carcinoma

NCT05531916 2026-04-30

CIPN

182 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07555860 2026-04-29

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

28 enrolled

Phase NA Not yet recruiting

Nasopharyngeal Carcinoma

NCT07552883 2026-04-27

EPoRN

40 enrolled

Nasopharyngeal Carcinoma, Necrosis, Radiation Injuries

NCT02633202 2026-04-24

Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era

Phase 3 Completed

338 enrolled

Nasopharyngeal Carcinoma

NCT06662058 2026-04-23

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Phase NA Recruiting

118 enrolled

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07540390 2026-04-22

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

442 enrolled

Nasopharyngeal Carcinoma

NCT03010150 2026-04-15

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

Recruiting

471 enrolled

Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms

NCT06093061 2026-04-14

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT07201337 2026-04-06

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

700 enrolled

Phase EARLY_PHASE1 Recruiting

Nasopharyngeal Carcinoma

NCT05587543 2026-04-02

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

24 enrolled

Nasopharyngeal Carcinoma

NCT06788002 2026-04-02

Light

26 enrolled

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07247201 2026-03-30

AlloNK1

31 enrolled

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07180173 2026-03-24

Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study

Completed

7 enrolled

Phase 1 Active not recruiting

Nasopharyngeal Carcinoma, Neoplasms

NCT02287311 2026-03-23

MABEL

38 enrolled 16 charts

Head & NeckLymphoid

Nasopharyngeal Carcinoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Smooth Muscle Tumor

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Phase 1/2 Not yet recruiting

52 enrolled

Nasopharyngeal Carcinoma

NCT07362979 2026-03-17

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

243 enrolled

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors